Recursion Pharmaceuticals Inc Cl A(RXRX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low3.19
Day High3.36
Open:3.20
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
TD Cowen Keeps Their Hold Rating on Recursion Pharmaceuticals (RXRX)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Geron (GERN), Zimmer Biomet Holdings (ZBH) and Recursion Pharmaceuticals (RXRX)
Tipranks
Recursion updates Q2 results and AI-driven pipeline
Motley Fool
3 Stocks With the Most Upside by the End of 2026
Newswire.ca
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
Motley Fool
Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?
Motley Fool
2 Beaten-Down Stocks That Still Aren't Worth Buying
Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Motley Fool
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
Motley Fool
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
Newswire.ca
As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data
Newswire.ca
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
Motley Fool
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool
Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market
Motley Fool
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying
Tipranks
Recursion Shareholders Reelect Directors and Approve Governance Matters
Motley Fool
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
GlobeNewswire
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Profile

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering. Recursion Pharmaceuticals Inc. is based in SALT LAKE CITY.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.